01 / DESIGN
What was studied?
This single-center phase 1b study randomized 96 adults with overweight or obesity. Both comparison groups received semaglutide, with either cagrilintide or matched placebo added.
02 / FINDINGS
What did the researchers report?
The investigators examined adverse events and drug exposure. Exploratory weight findings favored some combination groups; gastrointestinal events featured prominently in the safety observations.
03 / LIMITS
How should it be interpreted?
This was a small, early study with exploratory efficacy outcomes. Its comparator was not an untreated group. It is not a recipe for combining products, and larger trials are needed to assess broader effects.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.